# Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer

> **NCT00648102** · PHASE1 · COMPLETED · sponsor: **Celldex Therapeutics** · enrollment: 36 (estimated)

## Conditions studied

- Breast Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Bladder Cancer
- Ovarian Cancer

## Interventions

- **BIOLOGICAL:** CDX-1307

## Key facts

- **NCT ID:** NCT00648102
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2009-05
- **Final completion:** 2009-12
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2010-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00648102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00648102, "Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00648102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*